Cite
MLA Citation
S. Mazza et al.. “AF.50 SAFETY AND CLINICAL EFFICACY OF THE DOUBLE SWITCH FROM ORIGINATOR INFLIXIMAB TO BIOSIMILARS CT-P13 AND SB2 IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES (SCESICS): A MULTICENTER COHORT STUDY.” Digestive and liver disease, vol. 53, n.d., pp. S159–. http://access.bl.uk/ark:/81055/vdc_100144251708.0x000028